studied head and neck cancer (NHC) and NSCLC patients using 89Zr-cetuximab PET/CT but showed that SUVmax and SUVmean had no direct relationship between EGFR immunohistochemistry (IHC) score and tumor-to-background ratio (TBR) (55). Here, EGFR is linked to neoplasm.